Effects of transverse aortic constriction-induced left ventricular dysfunction on pulmonary vascular remodeling in rats and its relationship with bone morphogenetic protein 7
Basic Medicine|更新时间:2026-01-09
|
Effects of transverse aortic constriction-induced left ventricular dysfunction on pulmonary vascular remodeling in rats and its relationship with bone morphogenetic protein 7
Journal of Third Military Medical UniversityVol. 42, Issue 14, Pages: 1385-1391(2020)
作者机构:
1.400010 重庆,重庆医科大学附属第二医院心血管内科
2.518055 广东 深圳,深圳大学总医院心血管内科
3.400037 重庆,陆军军医大学(第三军医大学)第二附属医院心血管内科
作者简介:
基金信息:
the Basic and Applied Science Research Fund of Guangdong Province(2019A1515011421);the Sci-Tech Research Promotion Program of Shenzhen University General Hospital(SUGH2018QD048);the Project of Shenzhen Municipal Sci-Tech Research Development Plan(JCYJ20190808122207499)
Junhao HU, Xiaojing WU, Wenzhu GU, et al. Effects of transverse aortic constriction-induced left ventricular dysfunction on pulmonary vascular remodeling in rats and its relationship with bone morphogenetic protein 7[J]. Journal of Third Military Medical University, 2020, 42(14): 1385-1391.
DOI:
Junhao HU, Xiaojing WU, Wenzhu GU, et al. Effects of transverse aortic constriction-induced left ventricular dysfunction on pulmonary vascular remodeling in rats and its relationship with bone morphogenetic protein 7[J]. Journal of Third Military Medical University, 2020, 42(14): 1385-1391. DOI: 10.16016/j.1000-5404.202002118.
Effects of transverse aortic constriction-induced left ventricular dysfunction on pulmonary vascular remodeling in rats and its relationship with bone morphogenetic protein 7
To study the effects of left ventricular dysfunction induced by transverse aortic constriction (TAC) on pulmonary vascular remodeling and hemodynamics
and the relationship with bone morphogenetic protein 7 (BMP7) expression in the lung tissues of rats.
Methods
2
Sixteen healthy male Sprague-Dawley rats were randomized equally into TAC model group and sham operation group. At the end of 9 weeks after the surgery
cardiac remodeling and the changes of cardiac functions were assessed by cardiac ultrasound. The pulmonary hemodynamic parameters and the right ventricular functions were evaluated by cardiac catheterization. HE and Masson staining was used to observe pulmonary vascular remodeling
left ventricular myocardial cell size and left ventricular myocardial cell fibrosis in the rats. The mRNA and protein levels of BMP7 in the lung tissues of the rats were detected using RT-qPCR and Western blotting.
Results
2
Compared with the sh
am-operated rats
the rats with TAC showed significantly increased left ventricular wall and septal thickness
increased left ventricular end-diastolic volume (
P
<
0.01)
and decreased left ventricular ejection fraction (
P
<
0.01). Hemodynamic analysis showed significant increases of the mean pulmonary arterial pressure (mPAP) and right ventricular systolic pressure (RVSP) in rats with TAC as compared with the sham-operated rats (
P
<
0.01). Pathological examination revealed that in rats with TAC
the cross-sectional area of the left ventricular cardiomyocytes increased significantly (
P
<
0.01) with obvious myocardial fibrosis (
P
<
0.01) and thickening of the medial layer of the pulmonary arterioles (
P
<
0.01) in comparison with the sham-operated group. The expression of BMP7 was decreased significantly at both the mRNA and protein levels in the pulmonary tissue in TAC group as compared with the sham-operated group (
P
<
0.05).
Conclusion
2
Pulmonary hypertension and pulmonary vascular remodeling caused by left ventricular remodeling and left ventricular dysfunction might be related to decreased pulmonary BMP7 expression in addition to the direct influence by changes in the hemodynamics
suggesting that the organ crosstalk between the heart and the lung might participate in the occurrence of pulmonary hypertension resulting from left heart diseases.
关键词
Keywords
references
WEITSMAN T, WEISZ G, FARKASH R, et al . Pulmonary hypertension with left heart disease: prevalence, temporal shifts in etiologies and outcome[J ] . Am J Med, 2017, 130(11): 1272-1279. DOI: 10.1016/j.amjmed.2017.05.003.
FAYYAZ A U, EDWARDS W D, MALESZEWSKI J J, et al . Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction[J ] . Circulation, 2018, 137(17): 1796-1810. DOI: 10.1161/circulationaha.117.031608.
MERINO D, VILLAR A V, GARCÍA R, et al . BMP-7 attenuates left ventricular remodelling under pressure overload and facilitates reverse remodelling and functional recovery[J ] . Cardiovasc Res, 2016, 110(3): 331-345. DOI: 10.1093/cvr/cvw076.
DIN S, SARATHCHANDRA P, YACOUB M H, et al . Interaction between bone morphogenetic proteins and endothelin-1 in human pulmonary artery smooth muscle[J ] . Vascul Pharmacol, 2009, 51(5/6): 344-349. DOI: 10.1016/j.vph.2009.09.001.
LIU D, WU B X, SUN N, et al . Elevated levels of circulating bone morphogenetic protein 7 predict mortality in pulmonary arterial hypertension[J ] . Chest, 2016, 150(2): 367-373. DOI: 10.1016/j.chest.2016.03.007.
ROSENKRANZ S, GIBBS J S R, WACHTER R, et al . Left ventricular heart failure and pulmonary hypertension[J ] . Eur Heart J, 2016, 37(12): 942-954. DOI: 10.1093/eurheartj/ehv512.
LAM C S, ROGER V L, RODEHEFFER R J, et al . Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study[J ] . J Am Coll Cardiol, 2009, 53(13): 1119-1126. DOI: 10.1016/j.jacc.2008.11.051.
SHAH A M, CLAGGETT B, SWEITZER N K, et al . Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial[J ] . Circ Heart Fail, 2014, 7(5): 740-751. DOI: 10.1161/CIRCHEARTFAILURE.114.001583.
LEUNG C C, MOONDRA V, CATHERWOOD E, et al . Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction[J ] . Am J Cardiol, 2010, 106(2): 284-286. DOI: 10.1016/j.amjcard.2010.02.039.
WANG Y X, QIAN L X, LIU D, et al . Bone morphogenetic protein-2 acts upstream of myocyte-specific enhancerfactor 2a to control embryonic cardiac contractility[J ] . Cardiovasc Res, 2007, 74(2): 290-303.
SUN B, HUO R, SHENG Y, et al . Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy[J ] . Hypertension, 2013, 61(2): 352-360. DOI: 10.1161/HYPERTENSIONAHA.111.00562.
SUN L J, YU J, QI S, et al . Bone morphogenetic protein-10 induces cardiomyocyte proliferation and improves cardiac function after myocardial infarction[J ] . J Cell Biochem, 2014, 115(11): 1868-1876. DOI: 10.1002/jcb.24856.
LONG L, ORMISTON M L, YANG X, et al . Selective enhancement of endothelial BMPR-Ⅱ with BMP9 reverses pulmonary arterial hypertension[J ] . Nat Med, 2015, 21(7): 777-785.